Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Nelson

Showing results (291-300 of 442) with videos related to

Pageof 45
Sort By:
AIDS (London, England)|April 26, 2007
Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behavioursMark Danta, David Brown, Sanjay Bhagani, et al.
AIDS (London, England)|June 26, 2007
Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistanceMarta Boffito, Alan Winston, Akil Jackson, et al.
AIDS (London, England)|February 15, 2021
Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudineMark Nelson, Alan Winston, Andrew Hill, et al.
Bioresource Technology|March 14, 2017
Fate of trace organic contaminants in oxic-settling-anoxic (OSA) process applied for biosolids reduction during wastewater treatmentGalilee U Semblante, Faisal I Hai, James McDonald, et al.
British Journal of Clinical Pharmacology|December 21, 2004
Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjectsMarta Boffito, David Back, Meredith Stainsby-Tron, et al.
Antiviral Therapy|July 21, 2004
Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimenMarta Boffito, Laura Dickinson, Andrew Hill, et al.
AIDS (London, England)|February 4, 2010
Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphomaSilvia Montoto, Jamie Wilson, Kate Shaw, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 14, 2020
Use of Coronary Artery Calcium Scoring to Improve Cardiovascular Risk Stratification and Guide Decisions to Start Statin Therapy in People Living With HIVBranca Pereira, Maria Mazzitelli, Ana Milinkovic, et al.
The Journal of Infection|September 30, 2015
Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programmeAndrea Gori, Manuela Doroana, Oksana Chernova, et al.
Antiviral Therapy|August 24, 2007
Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patientsLauro J Waters, Graeme Moyle, Stefano Bonora, et al.
Pageof 45

Showing results (291-300 of 442) with videos related to

Sort By:
Pageof 45
AIDS (London, England)|April 26, 2007
Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behavioursMark Danta, David Brown, Sanjay Bhagani, et al.
AIDS (London, England)|June 26, 2007
Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistanceMarta Boffito, Alan Winston, Akil Jackson, et al.
AIDS (London, England)|February 15, 2021
Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudineMark Nelson, Alan Winston, Andrew Hill, et al.
Bioresource Technology|March 14, 2017
Fate of trace organic contaminants in oxic-settling-anoxic (OSA) process applied for biosolids reduction during wastewater treatmentGalilee U Semblante, Faisal I Hai, James McDonald, et al.
British Journal of Clinical Pharmacology|December 21, 2004
Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjectsMarta Boffito, David Back, Meredith Stainsby-Tron, et al.
Antiviral Therapy|July 21, 2004
Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimenMarta Boffito, Laura Dickinson, Andrew Hill, et al.
AIDS (London, England)|February 4, 2010
Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphomaSilvia Montoto, Jamie Wilson, Kate Shaw, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 14, 2020
Use of Coronary Artery Calcium Scoring to Improve Cardiovascular Risk Stratification and Guide Decisions to Start Statin Therapy in People Living With HIVBranca Pereira, Maria Mazzitelli, Ana Milinkovic, et al.
The Journal of Infection|September 30, 2015
Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programmeAndrea Gori, Manuela Doroana, Oksana Chernova, et al.
Antiviral Therapy|August 24, 2007
Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patientsLauro J Waters, Graeme Moyle, Stefano Bonora, et al.
Pageof 45